Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response

Bone Marrow Transplantation volume 48, pages 1484–1485 (2013)Cite this article

Subjects

Peripheral T/NK-cell lymphomas are uncommon disorders resulting from clonal proliferation of mature post-thymic lymphocytes and accounting for 5–10% of all non-Hodgkin’s lymphomas.1 Their optimal therapy remains to be established because of the lack of randomized trials. The disease is often diagnosed at advanced stages with unfavorable international prognostic index (IPI) scores. As a consequence, excluding ALK-positive anaplastic large cell lymphomas (ALCL) and indolent mycosis fungoides, most patients have a poor prognosis. The international peripheral T-cell and NK/T-cell lymphoma project reported 5-year OS of <35% in peripheral T-cell lymphomas not otherwise specified (PTCL-NOS) with IPI scores ⩾2 at diagnosis, and in ALK-negative ALCL with IPI scores ⩾3.2, 3, 4 As the median age of patients diagnosed with PTCL is 62 years,2 allogeneic SCT (allo-SCT) can be considered as a therapeutic option in some patients. The role of allo-SCT in patients with relapsed PTCL has been investigated with encouraging results in chemosensitive diseases where long-term survival ranged from 69% to 81%.5, 6, 7 However, no study has specifically addressed the role of early allo-SCT in first response. Thus, in an effort to explore this therapeutic option in younger patients, we undertook a retrospective analysis of patients treated at our center with allo-SCT in first response.

The modest size of our study and its retrospective design preclude declaration of any firm conclusion. However, these preliminary data reported with a meaningful follow-up for aggressive lymphomas suggest that selected patients with high-risk PTCL (IPI⩾2) and a first response long enough to undergo allo-SCT might benefit from early transplantation in the course of their disease. These results are in line with previous studies reported in patients with relapsed but chemosensitive diseases, in whom long-term survival ranged from 69% to 81%.5, 6, 7 Collectively, these data suggest a potent graft-versus-lymphoma effect in patients with high-risk PTCL. Finally, it must be acknowledged that randomized studies are warranted to further delineate the optimal first line therapy in these patients. As a consequence, our center is currently participating in the ongoing ‘Auto versus Allo Transplantation in Peripheral T-Cell Lymphomas’ European study comparing both strategies in first response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Anderson JR, Armitage JO, Weisenburger DD . Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1998; 9: 717–720.

    Article  CAS  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124–4130.

    Article  Google Scholar 

  3. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117: 3402–3408.

    Article  CAS  Google Scholar 

  4. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496–5504.

    Article  CAS  Google Scholar 

  5. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.

    Article  Google Scholar 

  6. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. Société Française de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.

    Article  Google Scholar 

  7. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951–3958.

    Article  Google Scholar 

  8. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. International Harmonization Project on Lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Hématologie et de Thérapie Cellulaire, CHU Haut-Lévêque, Bordeaux, France

    M Robles, S Vigouroux, R Tabrizi, K Bouabdallah, M-S Dilhuydy, T Leguay, A Pigneux, P-Y Dumas, A Lascaux, C Duclos, G Marit & N Milpied

  2. Laboratoire d’Anatomie Pathologique, CHU Haut-Lévêque, Bordeaux, France

    M Parrens

  3. Université Bordeaux Segalen, Bordeaux, France

    A Pigneux, G Marit & N Milpied

Authors
  1. M Robles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Vigouroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Tabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M-S Dilhuydy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Parrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Leguay
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Pigneux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P-Y Dumas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Lascaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Duclos
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Marit
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Vigouroux.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robles, M., Vigouroux, S., Tabrizi, R. et al. Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response. Bone Marrow Transplant 48, 1484–1485 (2013). https://doi.org/10.1038/bmt.2013.86

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.86

This article is cited by

Search

Advanced search

Quick links